Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 11/2004

01-11-2004 | Controversies-Against

Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer’s disease in vivo?

Author: Agneta Nordberg

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2004

Login to get access

Excerpt

Alzheimer’s disease (AD) is becoming a great health and socio-economic problem all over the world. There is an increasing consensus that the production and accumulation of amyloid protein is central to the pathogenesis of AD. Brain imaging has undergone rapid development and we are presently approaching the exciting possibility that it will allow the tracing of brain amyloid in AD patients. A key question, however, is whether amyloid plaque imaging reflects AD brain pathology. …
Literature
1.
Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351–7.CrossRefPubMed
2.
Thal DR, Rub U, Orantoes M, Braak H. Phases of A-beta deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791–800.PubMed
3.
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256:184–5.PubMed
4.
Schönheit B, Zarski R, Ohm T. Spatial and temporal relationship between plaques and tanges in Alzheimer-pathology. Neurobiol Aging 2004;25:697–711.PubMed
5.
Nordberg A, Lundqvist H, Hartvig P, Lilja A, Långström B. Kinetic analysis of regional (S)(−)11C-nicotine binding in normal and Alzheimer brains—in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 1995;1:21–7.
6.
Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Azheimer’s disease. Neurology 1999;52:691–9.PubMed
7.
8.
DeKosky ST, Ikonomovic MD, Styren SD, Becket L, Wisniewski S, Bennett DA, et al. Upregulation of choline acetyltransferase activity in the hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145.CrossRefPubMed
9.
Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between levels of amyloid beta-peptide in the brain and cognitive decline. J Am Med Assoc 2000;283:1571–7.CrossRef
10.
Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc Natl Acad Sci U S A 2004;101:284–9.
11.
Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and β-amyloid. Arch Neurol 2003;60:1696–702.CrossRefPubMed
12.
Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA. Development of an anti-A-beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer’s disease. Mol Neurobiol 1994;9:107–13.PubMed
13.
Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, et al. Molecular targeting Azheimer’s amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 2002;11:315–29.CrossRefPubMed
14.
Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the betaamyloid protein of Alzheimer’s disease. Neurobiol Aging 1994;15:691–8.CrossRefPubMed
15.
Klunk WE, Engler H, Nordberg A, Bacskai BJ, Wang Y, Price J, et al. Imaging the pathology of Alzheimer’s diseases: amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am 2003;13:781–9.PubMed
16.
17.
Shoghi-Jadid K, Small D, Agdeppa ED, Kepe V, Ercoli LM, Read S, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brain of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24–35.CrossRefPubMed
18.
Klunk EW, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 2004;55:306–19.
19.
Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, Petric A, et al. Dialkylamino-6-acylmalonnonitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tool in Alzheimer’s disease. Mol Imaging Biol 2003;5:404–17.CrossRefPubMed
20.
Bresjanac M, Smid LM, Vovko TD, Petric A, Barrio JR, Popovic M. Molecular-imaging probe-2-(1-[6-[(fluoroethyl)(methyl)amino-2-naphthyl]ethylidene)malonitrile labels prion plaques in vitro. J Neurosci 2003;23:8029–33.
21.
Petersen RC, Doody R, Kurz A, Mohs RC, Rabin PV, Ritchie K, et al. Current concept in mild cognitive impairment. Arch Neurol 2001;58:1985–92.CrossRefPubMed
22.
Wolf H, Jelic V, Gertz HJ, Nordberg A, Juhlin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl 2003;179:52–76.CrossRefPubMed
23.
Klunk WE, Price JC, Lopresti BJ, Debnath ML, Holt DP, Meltzer C, et al. Human amyloid-imaging studies in controls, mild cognitive impairment and Alzheimer’s disease using Pittsburgh Compound-B. Ninth international conference on Alzheimer’s disease and related disorders, Philadelphia, Pennsylvania. USA, 17–22 July 2004, abstr O-3-03-05.
24.
Nordberg A, Engler H, Blomqvist G, Almkvist O, Ausén B, Wall A, Långström B. Imaging of amyloid in vivo in MCI and AD patients. Ninth international conference on Alzheimer’s disease and related disorders, Philadelphia, Pennsylvania. USA, 17–22 July 2004, abstr O-3-03-08.
25.
Cummings JL. Alzheimer’s disease. N Engl J Med 2004;351:56–67.
26.
Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46–54.PubMed
27.
Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003;9:448–52.CrossRefPubMed
28.
Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In vivo measurement of activated microglia in dementia. Lancet 2001;11:461–7.CrossRef
29.
Engler H, Lundberg PO, Ekbom K, Nennesmo I, Nilsson A, Bergström M, et al. Multitracer study with positron emission tomography in Creutzfeld-Jakob disease. Eur J Nucl Med Mol Imaging 2003;30:85–95.CrossRefPubMed
Metadata
Title
Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer’s disease in vivo?
Author
Agneta Nordberg
Publication date
01-11-2004
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-004-1677-8

Other articles of this Issue 11/2004

European Journal of Nuclear Medicine and Molecular Imaging 11/2004 Go to the issue

News & Views

November 2004

Original Article

Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma

Editorial Commentary

Maximising the benefit of integrated PET/CT: the road ahead

Review Article

Small animal PET: aspects of performance assessment

Molecular Imaging

A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia

Original Article

Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT?